Mycobacterial Infections due to PD-1 and PD-L1 Checkpoint Inhibitors
We have been discussing on PD-1 and PD-L1 during our webinars adlib as a â€˜rambanâ€™ for treatment of Advanced GU cancers. This article being provided is a general article that indicates that Mycobacterial Infections, both TB and Atypical Mycobacterial Infections, can occur with usage of ICIs. In some instances mortality has also been recorded with Mycobacterial infections after use of ICIs. Though rare as of now, the reported incidences are increasing.
India is the hot seat of Tuberculosis and there appear that there is an increasing use of ICIâ€™s in the treatment of many cancers. This makes it necessary for us to be more vigilant when using ICIâ€™s. The highest number of Mycobacterial Infections is recorded after use of these agents are for Lung Cancer. Use of ICI in GU cancers had a late start when compared to various other cancer subtypes with probably Kidney cancer leading the way. Nivolumab which is PD-1 led the way to be followed by other PD-L1 ICIs. The literature suggests that ICIs are less toxic than that are seen with other chemotherapeutic agents in common use. As mentioned, we in India with high TB burden should be extra vigilant regarding this when using ICIs. These agents are costly and less affordable for many financially strapped Indians as indicated in its pricing. Currently only 3 ICIs are approved by DGCI. They are Nivolumab, Atezolizumab and Pembrolizumab. The cost of drugs in Indian Rs varies depending on strength.
Nivolumab â€“ Cost ranges from Rs 39000 for 40mg strength to Rs 96000 for 100 mg strength.
Atezolizumab â€“ 1200mg, 20 Ml vial cost Rs 3 Lakhs
Pembrolizumab â€“ Rs 1.2 lakh a vial, Rs 2.6 lakh for 100mg
The price appears to vary from Distributor to Distributor.
With warm Regards,